following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv). .
he said: "our research shows that people, on average, believe that only 34 per cent of protection claims are paid out by insurance companies. .
.
.